Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 18/20 | 0.38 |
| ▸ | THRA | P10827 | 17/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.33 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.33 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28561079 | 1.00 | THRB (0.38) | THRBTHRACYP2C9UGT1A1ABCG2 | |
| SCHEMBL21769751 | 1.00 | THRB (0.38) | THRBTHRACYP2C9UGT1A1ABCG2 | |
| SCHEMBL38650578 | 1.00 | THRB (0.38) | THRBTHRACYP2C9UGT1A1ABCG2 | |
| SCHEMBL30398362 | 0.80 | THRA (0.41) | THRBTHRACYP2C9UGT1A1ABCG2 | |
| SCHEMBL22660386 | 0.80 | THRA (0.41) | THRBTHRACYP2C9UGT1A1ABCG2 | |
| SCHEMBL13116309 | 0.80 | THRB (0.39) | THRBTHRACYP2C9UGT1A1ABCG2 | |
| SCHEMBL30820597 | 0.80 | THRB (0.39) | THRBTHRACYP2C9UGT1A1ABCG2 | |
| SCHEMBL21749457 | 0.78 | THRB (0.62) | THRBTHRACYP2C9UGT1A1ABCG2 | |
| SCHEMBL21749485 | 0.78 | THRB (0.62) | THRBTHRACYP2C9UGT1A1ABCG2 | |
| SCHEMBL28561243 | 0.78 | THRB (0.41) | THRBTHRACYP2C9UGT1A1ABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3840755-B1 | THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS | TERNS INC (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20250236615-A1 | THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS | Terns, Inc. | 2025-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250236615-A1 | THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS | THRB, THRA, TSHR | THRB 1/4885THRA 2/4885CYP2C9 3768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.